{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:51:30Z","timestamp":1781736690669,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BioMolTox , European Union","award":["Class: 643-02\/23-01\/00016, Reg. no. 533-03-23-0006"],"award-info":[{"award-number":["Class: 643-02\/23-01\/00016, Reg. no. 533-03-23-0006"]}]},{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["UIP-2019-04-5692"],"award-info":[{"award-number":["UIP-2019-04-5692"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronary angiography induces oxidative stress through contrast media exposure and ionizing radiation, potentially contributing to vascular and renal injury. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exert antioxidant and anti-inflammatory effects beyond glycemic control. We investigated whether a single pre-procedural dose of empagliflozin modulates oxidative stress and inflammatory glycosylation patterns in non-diabetic patients undergoing elective coronary angiography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, randomized, double-blind study, 60 patients undergoing elective coronary angiography were assigned to standard care or empagliflozin 10\u00a0mg administered 2\u00a0h before the procedure. Blood samples were collected at baseline, 4\u00a0h, and 24\u00a0h post-procedure. Total antioxidant capacity (TAC), oxidative DNA damage (alkaline comet assay), and N-glycosylation profiles of immunoglobulin G (IgG) and total plasma proteins were analyzed. Longitudinal changes were assessed using mixed-effects models with correction for multiple testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics and procedural variables were comparable between groups. Empagliflozin administration was associated with attenuation of oxidative DNA damage 24\u00a0h after angiography and stabilization of antioxidant capacity compared with standard care. Directional shifts in IgG N-glycosylation toward a less pro-inflammatory profile were observed in the intervention group, including reduced agalactosylated and core-fucosylated glycans and relative preservation of galactosylated structures. Similar modulatory trends were detected in total plasma protein glycosylation patterns. Although several glycomic changes did not reach statistical significance after correction for multiple testing, the overall biological signal consistently favored reduced oxidative and inflammatory activation in the empagliflozin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A single pre-procedural dose of empagliflozin was associated with attenuation of oxidative stress-related DNA damage and modulation of inflammatory glycosylation patterns following coronary angiography. These findings suggest a potential peri-procedural cytoprotective role of SGLT2 inhibition that warrants confirmation in larger studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN11022820. Registered 13 October 2025. Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-026-00304-5","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:03:19Z","timestamp":1781733799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients"],"prefix":"10.1186","volume":"12","author":[{"given":"Katica Cvitkusic","family":"Lukenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cipak","family":"Gasparovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Milic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Radovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frano","family":"Vuckovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domagoj","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gudelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"304_CR1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"304_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-024-03570-6","volume":"25","author":"Y Li","year":"2024","unstructured":"Li Y, Wang J. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrol. 2024;25:140.","journal-title":"BMC Nephrol"},{"key":"304_CR3","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.3390\/ijms24076272","volume":"24","author":"KC Siaravas","year":"2023","unstructured":"Siaravas KC, Katsouras CS, Sioka C. Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int J Mol Sci. 2023;24:6272.","journal-title":"Int J Mol Sci"},{"key":"304_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/apha.12646","volume":"219","author":"PM Vanhoutte","year":"2017","unstructured":"Vanhoutte PM, Shimokawa H, Feletou M, Tang EHC. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol Oxf Engl. 2017;219:22\u201396.","journal-title":"Acta Physiol Oxf Engl"},{"key":"304_CR5","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.cell.2022.06.010","volume":"185","author":"JO Lundberg","year":"2022","unstructured":"Lundberg JO, Weitzberg E. Nitric oxide signaling in health and disease. Cell. 2022;185:2853\u201378.","journal-title":"Cell"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/joim.12465","volume":"280","author":"JM Tarbell","year":"2016","unstructured":"Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med. 2016;280:97\u2013113.","journal-title":"J Intern Med"},{"key":"304_CR7","doi-asserted-by":"crossref","unstructured":"Milusev A, Rieben R, Sorvillo N. The endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders. Front Cardiovasc Med. 2022;9.","DOI":"10.3389\/fcvm.2022.897087"},{"key":"304_CR8","doi-asserted-by":"crossref","unstructured":"Vittum Z, Cocchiaro S, Mensah SA. Basal endothelial glycocalyx\u2019s response to shear stress: a review of structure, function, and clinical implications. Front Cell Dev Biol. 2024;12.","DOI":"10.3389\/fcell.2024.1371769"},{"key":"304_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"304_CR10","first-page":"1","volume":"9","author":"M He","year":"2024","unstructured":"He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct Target Ther. 2024;9:1\u201333.","journal-title":"Signal Transduct Target Ther"},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/brv.12820","volume":"97","author":"C Toustou","year":"2022","unstructured":"Toustou C, Walet-Balieu M-L, Kiefer-Meyer M-C, et al. Towards understanding the extensive diversity of protein N-glycan structures in eukaryotes. Biol Rev Camb Philos Soc. 2022;97:732\u201348.","journal-title":"Biol Rev Camb Philos Soc"},{"key":"304_CR12","doi-asserted-by":"publisher","first-page":"106667","DOI":"10.1016\/j.phrs.2023.106667","volume":"188","author":"E Osto","year":"2023","unstructured":"Osto E, Bonacina F, Pirillo A, Norata GD. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacol Res. 2023;188:106667.","journal-title":"Pharmacol Res"},{"key":"304_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","volume":"20","author":"DV O\u2019Hara","year":"2024","unstructured":"O\u2019Hara DV, Lam CSP, McMurray JJV, et al. Applications of SGLT2 inhibitors beyond glycaemic control. Nat Rev Nephrol. 2024;20:513\u201329.","journal-title":"Nat Rev Nephrol"},{"key":"304_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761\u201372.","journal-title":"Nat Rev Cardiol"},{"key":"304_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0003-2697(02)00652-8","volume":"316","author":"F Tatzber","year":"2003","unstructured":"Tatzber F, Griebenow S, Wonisch W, Winkler R. Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera. Anal Biochem. 2003;316:147\u201353.","journal-title":"Anal Biochem"},{"key":"304_CR17","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbadis.2018.03.018","volume":"1864","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Salo PP, Trbojevi\u0107-Akma\u010di\u0107 I, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2034\u20139.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"304_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mrgentox.2019.03.009","volume":"843","author":"M Mili\u0107","year":"2019","unstructured":"Mili\u0107 M, O\u017evald I, Vinkovi\u0107 Vr\u010dek I, et al. Alkaline comet assay results on fresh and one-year frozen whole blood in small volume without cryo-protection in a group of people with different health status. Mutat Res Genet Toxicol Environ Mutagen. 2019;843:3\u201310.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"304_CR19","doi-asserted-by":"publisher","first-page":"108371","DOI":"10.1016\/j.mrrev.2021.108371","volume":"787","author":"M Mili\u0107","year":"2021","unstructured":"Mili\u0107 M, Ceppi M, Bruzzone M, et al. The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders. Mutat Res Rev Mutat Res. 2021;787:108371.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"304_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/picr.PICR_91_19","volume":"10","author":"R Aggarwal","year":"2019","unstructured":"Aggarwal R, Ranganathan P. Study designs: Part 4 \u2013 Interventional studies. Perspect Clin Res. 2019;10:137\u20139.","journal-title":"Perspect Clin Res"},{"issue":"3","key":"304_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"304_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s42255-022-00591-z","volume":"4","author":"MP Murphy","year":"2022","unstructured":"Murphy MP, Bayir H, Belousov V, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4:651\u201362.","journal-title":"Nat Metab"},{"key":"304_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0002-8703(03)00407-1","volume":"146","author":"A Goldberg","year":"2003","unstructured":"Goldberg A, Zinder O, Zdorovyak A, et al. Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am Heart J. 2003;146:819\u201323.","journal-title":"Am Heart J"},{"key":"304_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jcmg.2022.03.016","volume":"15","author":"M Ferencik","year":"2022","unstructured":"Ferencik M, Mayrhofer T, Lu MT, et al. Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. JACC Cardiovasc Imaging. 2022;15:1427\u201338.","journal-title":"JACC Cardiovasc Imaging"},{"key":"304_CR25","doi-asserted-by":"crossref","unstructured":"Wang D, Liu J, Zhong L, et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13.","DOI":"10.3389\/fphar.2022.1045235"},{"key":"304_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","volume":"12","author":"PK Judge","year":"2024","unstructured":"Judge PK, Staplin N, Mayne KJ, et al. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"304_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","volume":"9","author":"A Yasui","year":"2018","unstructured":"Yasui A, Lee G, Hirase T, et al. Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes. Diabetes Ther. 2018;9:863\u201371.","journal-title":"Diabetes Ther"},{"key":"304_CR28","doi-asserted-by":"publisher","first-page":"20386","DOI":"10.1038\/s41598-024-71416-0","volume":"14","author":"Y Hirashima","year":"2024","unstructured":"Hirashima Y, Nakano T, Torisu K, Aihara S, Wakisaka M, Kitazono T. SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis. Sci Rep. 2024;14:20386.","journal-title":"Sci Rep"},{"key":"304_CR29","first-page":"58","volume":"10","author":"AJ Daniele","year":"2024","unstructured":"Daniele AJ, Gregorietti V, Costa D. L\u00f3pez \u2013 Fern\u00e1ndez T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD \u2013 PILOT trial. Cardio-Oncol. 2024;10:58.","journal-title":"Cardio-Oncol"},{"key":"304_CR30","doi-asserted-by":"publisher","first-page":"109506","DOI":"10.1016\/j.cellsig.2019.109506","volume":"68","author":"NA Das","year":"2020","unstructured":"Das NA, Carpenter AJ, Belenchia A, et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. Cell Signal. 2020;68:109506.","journal-title":"Cell Signal"},{"key":"304_CR31","doi-asserted-by":"publisher","unstructured":"Eshraghi A, Khalesi S, Amini K, et al. Empagliflozin ameliorates the oxidative stress profile in type 2 diabetic patients with heart failure and reduced ejection fraction: results of a randomized, double-blind, placebo-controlled study. Rev Recent Clin Trials 2025 Published onlineJanuary. 2025;6. https:\/\/doi.org\/10.2174\/0115748871323540241212060946.","DOI":"10.2174\/0115748871323540241212060946"},{"key":"304_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-023-01822-7","volume":"22","author":"J Hoehlschen","year":"2023","unstructured":"Hoehlschen J, Hofreither D, Tomin T, Birner-Gruenberger R. Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review. Cardiovasc Diabetol. 2023;22:101.","journal-title":"Cardiovasc Diabetol"},{"key":"304_CR33","first-page":"71","volume":"56","author":"M El-Daly","year":"2018","unstructured":"El-Daly M, Pulakazhi Venu VK, Saifeddine M, et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vasc Pharmacol. 2018;56:71.","journal-title":"Vasc Pharmacol"},{"key":"304_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol"},{"key":"304_CR35","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","volume":"42","author":"H Kondo","year":"2021","unstructured":"Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947\u201360.","journal-title":"Eur Heart J"},{"key":"304_CR36","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.intimp.2023.110072","volume":"118","author":"Y Chen","year":"2023","unstructured":"Chen Y, Peng D. New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. Int Immunopharmacol. 2023;118:110072.","journal-title":"Int Immunopharmacol"},{"key":"304_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","volume":"333","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65\u201379.","journal-title":"Cell Immunol"},{"key":"304_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/biom13040605","volume":"13","author":"B Plav\u0161a","year":"2023","unstructured":"Plav\u0161a B, Szavits-Nossan J, Blivajs A, et al. The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation. Biomolecules. 2023;13:605.","journal-title":"Biomolecules"},{"key":"304_CR39","doi-asserted-by":"publisher","first-page":"153879","DOI":"10.1016\/j.tox.2024.153879","volume":"506","author":"H Badreldin","year":"2024","unstructured":"Badreldin H, El-Karef A, Ibrahim T, Elshal M. Targeting Nrf2\/HO-1 and NF-\u03baB\/TNF-\u03b1 signaling pathways with empagliflozin protects against atrial fibrillation-induced acute kidney injury in rats. Toxicology. 2024;506:153879.","journal-title":"Toxicology"},{"key":"304_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","volume":"16","author":"R Zhang","year":"2024","unstructured":"Zhang R, Xie Q, Lu X, Fan R, Tong N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr. 2024;16:99.","journal-title":"Diabetol Metab Syndr"},{"key":"304_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34\u201347.","journal-title":"Nat Rev Immunol"},{"key":"304_CR42","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733\u201340.","journal-title":"J Biol Chem"},{"key":"304_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/glycob\/cwaa018","volume":"30","author":"EB Irvine","year":"2020","unstructured":"Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology. 2020;30:241\u201353.","journal-title":"Glycobiology"},{"key":"304_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eng.2022.12.004","volume":"26","author":"Z Wu","year":"2023","unstructured":"Wu Z, Guo Z, Zheng Y, et al. IgG N-Glycosylation Cardiovascular Age Tracks Cardiovascular Risk Beyond Calendar Age. Engineering. 2023;26:99\u2013107.","journal-title":"Engineering"},{"key":"304_CR45","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.bbagen.2015.10.016","volume":"1860","author":"G Lauc","year":"2016","unstructured":"Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: The human N-glycome. Biochim Biophys Acta. 2016;1860:1574\u201382.","journal-title":"Biochim Biophys Acta"},{"key":"304_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0959-440X(02)00365-2","volume":"12","author":"R Kannagi","year":"2002","unstructured":"Kannagi R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struct Biol. 2002;12:599\u2013608.","journal-title":"Curr Opin Struct Biol"},{"key":"304_CR47","doi-asserted-by":"crossref","unstructured":"Marciel MP, Haldar B, Hwang J, Bhalerao N, Bellis SL. Chapter five - role of tumor cell sialylation in pancreatic cancer progression. In: Abbott KL, Dimitroff CJ, editors. Advances in Cancer Research. Novel methods and pathways in cancer glycobiology research. Academic Press, 2023;157:123\u2013155.","DOI":"10.1016\/bs.acr.2022.07.003"},{"key":"304_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10719-015-9626-2","volume":"33","author":"F Clerc","year":"2016","unstructured":"Clerc F, Reiding KR, Jansen BC, Kammeijer GSM, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33:309\u201343.","journal-title":"Glycoconj J"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00304-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:03:21Z","timestamp":1781733801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00304-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00304-5","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of the General Hospital Dr. Josip Ben\u010devi\u0107 in Slavonski Brod (Approval No. 04000000\/23\u201365), the Ethics Committee of the Institute for Medical Research and Occupational Health in Zagreb (Approval No. 100\u2009\u2212\u200921\/23\u2009\u2212\u200912), and the Bioethics Committee of the Ru\u0111er Bo\u0161kovi\u0107 Institute in Zagreb (Approval No. BEP-5968\/1-2023). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion. This investigator-initiated study was conducted within institutional clinical settings without patient or public involvement in the design, conduct, reporting, or dissemination of the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}